Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
23 Total results for product and free and sample content found
Pharmaprojects
By Ian Lloyd 13 Apr 2017
Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2017, this supplement takes a look at the industry’s success stories of 2016 – the drugs which were launched on to the market for the first time during the year.
Biomedtracker
23 Mar 2017
There is no doubt that 2016 will be marked as year of surprising results. None more so than how life science companies fared in the capital markets.
Topic Business strategies
Pharmaprojects
27 Feb 2017
Over 350 million people worldwide are suffering from rare diseases. Which is why it is necessary to understand the rare disease landscape to date.
RxScorecard
28 Nov 2016
When it comes to value frameworks, one thing is certain, they’re here to stay.
Topic Reimbursement Deal trends
RxScorecard
23 Nov 2016
See how the value of drugs differentiate therapies by sub-population. Find out where the disproportionate value of your drug lies alongside competitors. Uncover demonstrable differentiated value when entering a crowded market. Discover the power of RxScorecard™.
Topic Reimbursement
Medtrack
By Patricia Giglio 14 Nov 2016
Partnering came into use twenty-odd years ago when pharmaceutical companies began working with biotech and increasingly sought external discovery and development opportunities.
RxScorecard
14 Nov 2016
Indication-based pricing isn’t just coming. It’s here.
Topic Reimbursement
Datamonitor Healthcare
By Colin White, Robert Jeng & Jolene Lau 26 Oct 2016
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
Topic immuno-oncology
Datamonitor Healthcare
By Ljlal Syed, Mark Lansdell and David Abramson 20 Oct 2016
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
Topic Deal trends
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
